{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:31:00Z","timestamp":1767915060182,"version":"3.49.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2051,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1093\/annonc\/mdu021","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T10:38:42Z","timestamp":1395743922000},"page":"763-773","source":"Crossref","is-referenced-by-count":65,"title":["Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"M.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Andre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jahanzeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Papazisis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Porta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu021_bb0010","series-title":"Afinitor\u00ae (everolimus) tablets [summary of product characteristics]","year":"2012"},{"key":"10.1093\/annonc\/mdu021_bb0015","series-title":"Afinitor\u00ae (everolimus) tablets [package insert]","year":"2012"},{"key":"10.1093\/annonc\/mdu021_bb0020","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0025","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","article-title":"Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors","volume":"26","author":"Tabernero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0030","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu021_bb0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu021_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11523-011-0174-9","article-title":"Common toxicities of mammalian target of rapamycin inhibitors","volume":"6","author":"Soefje","year":"2011","journal-title":"Target Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0045","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu021_bb0050","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu021_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","article-title":"Everolimus: side effect profile and management of toxicities in breast cancer","volume":"140","author":"Paplomata","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdu021_bb0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdu021_bb0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdu021_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdu021_bb0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri3198","article-title":"Regulation and function of mTOR signalling in T cell fate decisions","volume":"12","author":"Chi","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"10.1093\/annonc\/mdu021_bb0080","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.559","article-title":"Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial","author":"Piccart","year":"2012"},{"key":"10.1093\/annonc\/mdu021_bb0085","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdu009","article-title":"Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2","volume":"25","author":"Rugo","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0090","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mds115","article-title":"Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma","volume":"23","author":"Albiges","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0095","first-page":"51","article-title":"Management of key adverse events associated with everolimus therapy","volume":"8","author":"Moldawer","year":"2010","journal-title":"Kidney Cancer J"},{"key":"10.1093\/annonc\/mdu021_bb0100","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1188\/11.CJON.E83-E89","article-title":"Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors","volume":"15","author":"Pilotte","year":"2011","journal-title":"Clin J Oncol Nurs"},{"key":"10.1093\/annonc\/mdu021_bb0105","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu021_bb0110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1093\/annonc\/mdu021_bb0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1634\/theoncologist.2011-0111","article-title":"Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review","volume":"17","author":"Boers-Doets","year":"2012","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdu021_bb0120","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.oraloncology.2012.11.008","article-title":"A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients","volume":"49","author":"Martins","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0130","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1164\/rccm.200911-1720OC","article-title":"Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma","volume":"182","author":"White","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1093\/annonc\/mdu021_bb0135","article-title":"Everolimus-related adverse events: safety insights from BOLERO-2","author":"Rugo","year":"2013"},{"key":"10.1093\/annonc\/mdu021_bb0140","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.oraloncology.2011.08.009","article-title":"Clinical presentation and management of mTOR inhibitor-associated stomatitis","volume":"47","author":"de Oliveira","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0145","unstructured":"clinicaltrials.gov. Open-label, phase II, study of everolimus plus letrozole in postmenopausal women with ER+ metastatic breast cancer (Bolero-4). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01698918?term=bolero-4&rank=1 (11 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu021_bb0150","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.ejca.2011.03.017","article-title":"Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues","volume":"47","author":"Ferte","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu021_bb0155","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0160","first-page":"E223","article-title":"Management of stomatitis associated with mTOR inhibitors in hormone receptor-positive\/HER2-negative advanced breast cancer: clinical experiences from a single center","volume":"40","author":"Divers","year":"2013","journal-title":"Oncol Nurs Forum"},{"issue":"3","key":"10.1093\/annonc\/mdu021_bb0165","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/bju.12420","article-title":"mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes","volume":"113","author":"Atkinson","year":"2014","journal-title":"BJU Int"},{"issue":"4","key":"10.1093\/annonc\/mdu021_bb0170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3904\/kjm.2012.83.4.520","article-title":"Everolimus-induced interstitial pneumonitits in a patient with metastatic renal cell carcinoma: a case report","volume":"83","author":"Lee","year":"2012","journal-title":"Korean J Med"},{"issue":"24 suppl 3","key":"10.1093\/annonc\/mdu021_bb0175","article-title":"Non-infectious pneumonitis (NIP) in breast cancer (BC) patients treated with everolimus (Afinitor\u2122) containing therapy: analysis of five studies","volume":"69","author":"Jerusalem","year":"2009","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdu021_bb0180","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.7_suppl.319","article-title":"Effect of everolimus therapy on skeletal muscle wasting in patients with metastatic renal cell carcinoma (mRCC): results from a placebo-controlled study","author":"Albiges","year":"2011"},{"key":"10.1093\/annonc\/mdu021_bb0185","unstructured":"American Diabetes Association. Diabetes Basics. http:\/\/www.diabetes.org\/diabetes-basics\/diagnosis\/?loc=DropDownDB-diagnosis (11 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu021_bb0190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/CAD.0b013e32833760bf","article-title":"Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma","volume":"21","author":"Rodriguez-Pascual","year":"2010","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdu021_bb0195","unstructured":"National Institutes of Health. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. http:\/\/www.nhlbi.nih.gov\/guidelines\/cholesterol\/atp3full.pdf (11 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu021_bb0200","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12282-011-0307-0","article-title":"From improved survival to potential cure in patients with metastatic breast cancer","volume":"19","author":"Kobayashi","year":"2012","journal-title":"Breast Cancer"},{"key":"10.1093\/annonc\/mdu021_bb0205","first-page":"921","article-title":"Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update","volume":"169","author":"Genest","year":"2003","journal-title":"CMAJ"},{"key":"10.1093\/annonc\/mdu021_bb0210","unstructured":"International task force for prevention of coronary heart disease. Treatment guidelines for dyslipidemia. http:\/\/www.chd-taskforce.com\/pdf\/2004_06_09_zurich.pdf (11 December 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdu021_bb0215","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"10.1093\/annonc\/mdu021_bb0220","first-page":"627","article-title":"A status report on drug-associated acne and acneiform eruptions","volume":"9","author":"Momin","year":"2010","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1093\/annonc\/mdu021_bb0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000017841","article-title":"Acneiform dermatoses","volume":"196","author":"Plewig","year":"1998","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdu021_bb0230","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e19624","article-title":"Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis","author":"Ramirez-Fort","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/annonc\/mdu021_bb0235","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdu021_bb0240","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1093\/jnci\/djr188","article-title":"The influence of comorbidities on overall survival among older women diagnosed with breast cancer","volume":"103","author":"Patnaik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu021_bb0245","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/13697137.2010.539723","article-title":"Glucose tolerance of premenopausal women after menopause due to surgical removal of ovaries","volume":"14","author":"Pirimoglu","year":"2011","journal-title":"Climacteric"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419365044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/4\/763\/16703340\/mdu021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T20:05:52Z","timestamp":1598904352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419365044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0923753419365044"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu021","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}